Antimicrobial susceptibility of bacteria, isolated from patients treated at Jesenice General hospital in the period between 2004 and 2006

  • Helena Ribič
  • Urška Dermota
  • Irena Grmek-Košnik
  • Igor Rus
Keywords: bacterial sensitivity, general hospital, antibiotic, urinary tract infections, haemocultures

Abstract

Background: Antimicrobial resistance of bacteria is still one of the mayor problems in medicine. In the year 2006, microbiologists of the Institute of Public Health Kranj together with clinicians and pharmacist of Jesenice General Hospital prepared the programm of antimicrobial resistance surveillance of patients treated in the hospital. Some of the results are presented in this article.

Methods: In the retrospective study, bacterial strains, isolated from different samples were analysed. The strains were isolated and studied during the routine work of microbiology laboratory of IPH Kranj in the period between 2004 and 2006.

Results: The most frequently isolated bacteria from haemocultures was Escherichia coli (35.4 %). In the years 2004 and 2006, susceptibility of strains for ciprofloxacin was 95.7 % and 97.2 %, for parenteral cefuroxime (95.7 % and 94.4 %), for cefotaxime and gentamicin in both years 100 %. Susceptibility of E. coli strains from urine samples in patients from the department for internal medicine was in 2004 and 2006 for co-amoxiclav 88.5 % and 70.1 %, for co-trimoxazole 60.3 % and 81.3 %, for cefaclor 94.9 % and 89.7 %, for ciprofloxacin 83.3 % and 82.2 %. Among strains of Staphylococcus aureus, 100 % were sensitive to vancomycin and 99.3 % to linezolid in 2006. Among methicillin susceptible strains, sensitivity to erythromycin, clindamycin and ciprofloxacin lowered slightely in the three years period; in 2006 it was 87.6 %, 90.6 % and 89.1 %. Susceptibility of strains Pseudomonas aeruginosa was in 2006 similar comparing to 2004; it was 92 % for ceftazidime, 75 % for gentamicin, 64.6 % for ciprofloxacin and 96 % for imipenem. Among strains of Acinetobacter spp., sensitivity rate to ciprofloxacin, ceftazidime, piperacillin with tazobactam and gentamicin significantly fell in the year 2005 and stayed low in 2006.

Conclusions: The results of antimicrobial susceptibility surveillance and trends of susceptibility are intended to guide actions for resistance containment.

Downloads

Download data is not yet available.

References

Livermore DM, Macgowan AP, Wale MCJ. Surveillance of antimicrobial resistance. BMJ 1998; 317: 614-5.

Mackenzie FM, Struelens MJ, Towner KJ, Gould IM; ARPAC Steering Group; ARPAC. Consensus conference participants. Report of the consensus conference on antibiotic resistance, prevention and control (ARPAC). Clin Microbiol Infect 2005;11: 938-54.

McGowan Jr JE. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001; 7: 286-2.

Čižman M, ESAC raziskovalna skupina. Kaj vemo o rabi antibiotikov v slovenskih bolnišnicah. Med Razgl 2006; 45 Suppl 2: 11-5.

Čižman M, Pečar-Čad S, Slovenska skupina sodelavcev pri projektu ESAC. Uporaba protimikrobnih zdravil v Sloveniji in Evropi. Kje smo in kaj naj storimo? Med Razgl 2004; 43 Suppl 2: 3-10.

The Council of the European Union. Council recommendation of 15 November 2001 on the prudent use of antimicrobial agents in humane medicine. Official Journal of the European Communities 2002: L34/13-6.¸

Beović B. Metode racionalnega antibiotičnega zdravljenja. Med Razgl 2006; 45 Suppl 2: 17-22.

EARSS Management Team, members of the Advisory Board, national representatives of EARSS. EARSS annual reports 2001– 2005. Dosegljivo na URL: http://www.rivm.nl/earss

Kolman J, Gubina M, Müller-Premru M, Lorenčič-Robnik S, Žohar-Čretnik T, Harlander T, et al. Sodelovanje Slovenije v evropskem projektu EARSS - prikaz rezultatov deleža MRSA - izolatov iz hemokultur. Isis (Ljubl.) 2003; 12: 30-3.

Kolman J, Gubina M, Slovenska skupina za EARSS.Trendi občutljivosti invazivnih izolatov bakerije Staphylococcus aureus v Sloveniji in Evropi - rezultati projekta EARSS. Med Razgl 2004; 43 Suppl 2: 11-7.

Kolman J, Gubina M, Slovenska skupina za EARSS. Sodelovanje Slovenije v projektu EARSS. Med Razgl 2006; 45 Suppl 2: 3-10.

Bronzwaer S. European antimicrobial resistance surveillance as a part of a community strategy. Groningen: Rijksuniversiteit: 2003.

Anon. Analysis and presentation of cumulative antimicrobial susceptibility test data; Approved Guideline – Second edition. Document M39-A2. Villanova, PA: CLSI; 2005.

Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of clinical microbiology. 8th ed. Washington: ASM; 2003. p. 719-28.

Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Cryseobacterium, Moraxella, and other nonfermentative Gram-negative rods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of clinical microbiology. 8th ed. Washington: ASM; 2003. p. 749-79.

Anon. CLSI Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Document M100-S14. Villanova, PA: CLSI; 2004.

Anon. CLSI Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. Document M100-S15. Villanova, PA: CLSI; 2005.

Anon. CLSI Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Document M100-S16. Villanova, PA: CLSI; 2006.

Anon. CLSI Performance standards for antimicrobial disk susceptibility tests; Approved standard - Eighth Edition. CLSI document M2-A9. Villanova, PA: CLSI; 2006.

Anon. NCCLS Performance standards for antimicrobial disk susceptibility tests; Approved standard - Ninth Edition. NCCLS document M2-A8. Villanova, PA: NCCLS; 2002.

Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681-8.

Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48: 4606-10.

Golle A, Lorenčič-Robnik S, Novak D, Reberšek-Gorišek J. Odpornost bakterije Pseudomonas aeruginosa in bakterij iz rodu Acinetobacter, osamljenih iz kužnin bolnikov, zdravljenih v Splošni bolnišnici Maribor v obdobju 2001-2005. Med Razgl 2006; 45 Suppl 2: 39-48.

Kloos WE, BannermanTL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington: ASM; 1999. p. 264-82.

Tiemersma EW, Bronzwaer SLAM, Lyytikäinen O, Degener JE, Bruinsma N, Monen J, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 2004; 10: 1627-34.

How to Cite
1.
Ribič H, Dermota U, Grmek-Košnik I, Rus I. Antimicrobial susceptibility of bacteria, isolated from patients treated at Jesenice General hospital in the period between 2004 and 2006. ZdravVestn [Internet]. 1 [cited 15Nov.2019];76(11). Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/1909
Section
Professional article